US FDA extends review of Rhythm Pharma's drug for rare form of obesity-February 2024-www.financetom.com

US FDA extends review of Rhythm Pharma's drug for rare form of obesity

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA extends review of Rhythm Pharma's drug for rare form of obesity

Nov 7, 2025 5:09 AM

Nov 7 (Reuters) - Rhythm Pharmaceuticals ( RYTM ) said

on Friday the U.S. Food and Drug Administration has extended the

review period for expanded approval of its drug, Imcivree, as a

treatment for a rare form of obesity.

Previous page： Microbix Biosystems Says Ransomware Attack Led to Data Theft, No Operational Impact Next page： EuroHoldings Ltd. Announces Agreement to Acquire one 49,997 DWT Product Tanker Vessel, M/T Hellas Avatar, built in 2015

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Microbix Biosystems Says Ransomware Attack Led to Data Theft, No Operational Impact

Nov 5, 2025

08:26 AM EST, 11/05/2025 (MT Newswires) -- Microbix Biosystems ( MBXBF ) , a life sciences innovator, manufacturer, and exporter, on Wednesday addressed a cybersecurity incident relating to a ransomware attack that it said, had no impact on operations but involved the theft of data. The company said an international hacker group penetrated and corrupted a Microbix corporate server with...

EuroHoldings Ltd. Announces Agreement to Acquire one 49,997 DWT Product Tanker Vessel, M/T Hellas Avatar, built in 2015

Nov 5, 2025

ATHENS, Greece, Nov. 05, 2025 (GLOBE NEWSWIRE) -- EuroHoldings Ltd. ( EHLD ) (“EuroHoldings” or the “Company”) an owner and operator of ocean-going vessels and provider of seaborne transportation, announced today that it has signed a Memorandum of Agreement (MoA) to acquire, a medium-range (MR) product tanker vessel with capacity of 49,997 dwt, built in 2015 in South Korea, from...

Travel tech firm Sabre beats Q3 revenue estimates on higher bookings

Nov 5, 2025

Overview * Sabre Q3 revenue rises 3% yr/yr to $715 mln, beating analyst expectations * Adjusted EBITDA for Q3 misses analyst estimates * Company repaid ~$825 mln of debt from Hospitality Solutions sale proceeds Outlook * Sabre expects Q4 2025 Pro Forma Adjusted EBITDA of ~$110 mln, +2% YoY * Company forecasts full-year 2025 Pro Forma Adjusted EBITDA of ~$530...

Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast

Nov 5, 2025

(Reuters) -Cencora will invest over $1 billion through 2030 to expand its U.S. network, the drug distributor said on Wednesday, after forecasting adjusted profit for next year above Wall Street expectations. The company said it will build a second national distribution center in Harrison, Ohio, and new or enlarged sites in California and Alabama. The investment aligns with the Trump...